Disclaimer: This analysis was produced using autonomous AI agents and publicly available information. It is intended for informational and educational purposes only and should not be used to make investment decisions. CompetitiveIntelligence.com is an independent publication. For our relationship with Atacana Group, see our About page.
Company Name: Insira℠ (formerly Clarivate Life Sciences & Healthcare)
Headquarters: New York, NY
Website:
Founded: October 2026 (as Insira); heritage dates to Thomson Reuters Cortellis launch in 2012 and DRG acquisition in 2020
Ownership: Private — wholly owned by Altaris LLC (healthcare-focused PE; ~$10B equity capital)
Acquisition Price: $600M (LS&H segment acquired from Clarivate, NYSE: CLVT)
Acquisition Closed: October 6, 2026
Rebrand Launched: October 29, 2026
LS&H Segment Revenue: $389.8M (FY2025, pre-divestiture)
Employees: ~2,300 across 22 countries
Core Platforms: Cortellis, DRG, Dialog
Top 20 Pharma Penetration: 100% (Cortellis Regulatory Intelligence)
Top 50 Pharma Penetration: Used by Top 50 global pharma companies (CCI)
MedTech Penetration: 18 of top 20 medtech companies
Tagline: "Ahead of the question"
GM, R&D — Anne Lecocq: Leads the Cortellis product suite covering discovery, preclinical, clinical, regulatory, and safety phases
Altaris closed three acquisitions on October 6, 2026, assembling an integrated life sciences technology platform:
Understanding what Insira is trying to become reveals where they'll invest, which markets they'll prioritize, and what strategic moves to anticipate.
Insira's stated mission is to "double the success rate of treatment innovations, again and again". CEO Henry Levy described the launch as "a defining moment" and framed the company's purpose as "converting high-quality intelligence into immediate confidence, making the success of therapeutic and health technologies a predictable reality".
The company's inaugural blog post introduced the concept of "anticipatory intelligence" — moving "beyond reactive analysis toward anticipation" — as its strategic north star. Insira's brand positioning is built around the tagline "Ahead of the question," signaling a shift from search-and-retrieve intelligence to predictive, proactive insight delivery.
As a PE-backed entity under Altaris, Insira's financial goals follow the standard private equity playbook:
Revenue growth through pricing power and expansion. PE-owned healthcare data companies typically pursue 5–15% annual price increases at renewal, module unbundling, and premium tiering for AI capabilities. The $600M acquisition price against $389.8M FY2025 revenue implies a ~1.54x revenue multiple — well below industry norms — suggesting Altaris sees significant value creation opportunity through margin expansion and top-line growth.
Platform integration with Simulations Plus and CCG. The simultaneous closing of all three acquisitions on October 6, 2026, was deliberate. The combined platform — discovery (CCG/MOE), biosimulation (SLP/GastroPlus), safety (OFF-X), regulatory (CRI), competitive intelligence (CCI), commercialization (DRG) — enables cross-sell and bundle pricing that individual entities could not achieve alone.
Exit in 3–5 years. Healthcare PE typically targets exits via IPO or strategic sale within a 3–5 year hold period. Building a unified, AI-forward life sciences data platform would be attractive to both public markets and strategic acquirers (e.g., Thermo Fisher, Danaher, or a large data company expanding into life sciences).
Insira's launch messaging places AI at the center of its strategy. The October 29 press release specifically referenced "intuitive AI assistants, specialized agents and connectors" working within platforms, enterprise solutions, or customers' "own native tools". Key technology bets include:
Embedded agentic AI across Cortellis. Launched in August 2026 while still under Clarivate, agentic AI capabilities now span CCI (competitive intelligence workflows), CDDI (drug discovery natural language querying), and OFF-X (multi-agent safety intelligence). These capabilities transferred to Insira at close.
MCP interoperability across enterprise AI platforms. Cortellis Regulatory Intelligence is now available as both a Claude connector (March 2026) and a Microsoft Copilot connector (September–October 2026), with CMC Intelligence also available via Claude MCP. This positions Insira data as embeddable infrastructure within enterprise AI workflows.
Cross-platform AI integration with SLP/CCG. The most ambitious bet: connecting CCI agentic workflows with SLP biosimulation data and CCG computational chemistry to create an end-to-end AI-powered drug development intelligence platform. No integration has been announced yet, but the common ownership makes it structurally possible.
The Insira rebrand was executed with unusual speed — 23 days from deal close (October 6) to public launch (October 29). Key brand architecture decisions:
Insira operates as a differentiation leader in Porter's generic strategy framework, competing on data depth and breadth rather than price. The company controls what is arguably the most comprehensive proprietary life sciences dataset in the industry — 30+ years of expert-curated drug development, regulatory, safety, and commercial data assembled from the Thomson Reuters heritage, the Cortellis platform expansion, and the DRG acquisition.
Insira differentiates on three pillars:
Unrivaled pharma data depth. 100,000+ pipeline drugs (including 32,000+ in early research), 325,000+ clinical trials, 316,000+ company profiles, 6.9M+ patents, regulatory filings across 80+ jurisdictions, ~3,000 drug sales forecasts, and 1,450+ drug-level SWOT analyses.
Expert human curation + AI hybrid model. PhD- and MD-level analysts curate structured data ontologies that ground AI capabilities, reducing hallucination risk and ensuring traceability.
Full lifecycle coverage. From drug discovery (CDDI) through safety (OFF-X) through regulatory (CRI) through competitive intelligence (CCI) through commercialization (DRG), Insira covers more of the drug development lifecycle under a single platform than any competitor.
Insira employs an enterprise direct sales model targeting large pharmaceutical, biotechnology, medtech, and CRO organizations:
Insira uses a quote-based, opaque enterprise pricing model — no prices are published on their website or any review platform. Based on third-party data:
G2 explicitly notes that pricing information has not been provided by the vendor. Under PE ownership, price increases at renewal are expected.
Insira (and its predecessor) invests in thought leadership to reinforce category authority:
Porter's third component examines the mental models that guide a competitor's decisions. When these assumptions are wrong, they create exploitable blind spots.
"Deep proprietary data is an unbreachable moat." Insira's core assumption is that decades of expert-curated, structured life sciences data — particularly in regulatory, safety, and early-phase drug discovery — creates a competitive advantage that new entrants cannot replicate. This assumption is largely correct in the short term but faces erosion as AI-native platforms (AlphaSense, newer entrants) build knowledge graphs from public data sources and expert networks at a fraction of the cost and time. The question is whether curated depth beats automated breadth when AI can synthesize across both.
"A rebrand refreshes market perception." Insira is betting that separating from the Clarivate brand — which became associated with financial distress ($268.6M net loss in FY2025, $4.25B debt, stock trading below $2) — will give the LS&H business a clean slate with customers and prospects. The risk: brand confusion during the transition. Customers accustomed to "Cortellis by Clarivate" must now learn "Cortellis by Insira" — and some may use the transition as an evaluation window to consider alternatives.
"PE ownership means increased investment." Insira's messaging emphasizes "increased capital and focus" under Altaris. PE firms do invest in platforms they intend to grow — but they also extract through pricing increases, cost reduction, and margin expansion. Whether customers experience "increased investment" as better products or higher invoices will determine retention dynamics.
"AI augments rather than replaces human curation." Insira's approach combines AI with PhD/MD-level human expertise. This is a defensible position for safety-critical applications (pharmacovigilance, regulatory compliance) where accuracy matters more than speed. But for competitive intelligence use cases where speed and breadth matter more, the human-curation bottleneck may slow Insira's ability to match AI-native competitors that operate without it.
Insira's product pages and marketing position against Norstella/Citeline (pipeline data) and IQVIA (commercial data) as the primary competitive frame. AlphaSense acknowledged them as a peer in its 2026 pharma intelligence buyer's guide.
Insira appears to pay less attention to smaller AI-native CI platforms and consulting-led competitors that don't have comparable data assets but may compete for the same CI team budget through methodology, speed, and deliverable quality rather than data breadth.
Insira inherited a modular suite of life sciences intelligence products, each covering a different phase of the drug development and commercialization lifecycle.
Cortellis Competitive Intelligence (CCI) The flagship CI product. Covers 100,000+ pipeline drugs (including 32,000+ in early research), 3,000+ diseases, 316,000+ company profiles, ~3,000 drug sales forecasts, and 1,450+ drug-level SWOT analyses. Includes automated alerting, 20+ granular filters, and cross-module integration with regulatory, clinical, deals, and patent data. Agentic AI workflows launched August 2026 — claimed to transform "weeks of manual analysis into actionable intelligence delivered in hours".
Cortellis Regulatory Intelligence (CRI) Regulatory tracking across 80+ global jurisdictions. Trusted by "100% of the top 20 pharmaceutical companies and regulatory agencies worldwide." AI Assistant launched December 2025 with natural language querying, multilingual support, and cited answers. MCP integrations with Claude (March 2026) and Microsoft Copilot (September 2026).
Cortellis Drug Discovery Intelligence (CDDI) Preclinical and discovery-stage intelligence. Integrates ~540,000 bioactive compounds, 2.4M pharmacological studies, and 5,700+ drug targets. AI-powered natural language querying launched August 2026.
OFF-X — Translational Safety Intelligence Multi-agent AI architecture for proactive drug safety assessment. Combines AI agents with deterministic tools, grounded in curated translational safety data from journals, regulatory documents, clinical trial registries, and approval packages. Most technically advanced AI capability in the portfolio.
DRG (Decision Resources Group) Commercial analytics and market access intelligence. Includes DRG Commercial Analytics 360 (claims data, provider intelligence), market access advisory, and consulting services for commercialization strategy. Now part of Insira with explicit positioning around "market access and commercial decisions".
Additional Cortellis Modules: Deals Intelligence (M&A, licensing, partnering terms), Clinical Trials Intelligence (325,000+ trials, design benchmarking), Generics Intelligence (generic/biosimilar data, Newport patents database), CMC Intelligence (chemistry/manufacturing/controls requirements), Digital Health Intelligence, and Dialog (pharmacovigilance/literature review).
Insira's AI capabilities span three generations of development:
Note: During the transition period, Insira likely still relies on Clarivate's shared AI infrastructure under a transition services agreement. Clarivate's Q3 2026 earnings disclosed 465M+ AI API calls and 80+ in-market AI agents/assistants across its platform.
Under Altaris ownership (~$10B equity capital), Insira has access to significantly more investment capacity than it did under Clarivate, which was burdened with $4.25B in debt and a market cap below $1.5B. The $600M acquisition price at a ~1.54x revenue multiple gives Altaris substantial room for value creation through organic growth and operational improvement.
At closing, Clarivate received $488.4M in cash, a $75M unsecured senior note, and $25M in deferred consideration.
Insira does not appear in either the Gartner Magic Quadrant for Competitive & Market Intelligence or the Forrester Wave for Market & Competitive Intelligence Platforms — these analyst evaluations are dominated by horizontal platforms (AlphaSense, Crayon) rather than vertical pharma data providers.
Based on third-party reviews, independent analysis, and competitive intelligence:
Brand confusion from the rebrand. Customers accustomed to "Clarivate" and "Cortellis by Clarivate" must now process a new parent brand — "Insira" — that has zero market recognition. The 23-day rebrand speed is impressive operationally but leaves customers, procurement teams, and Google's algorithms catching up simultaneously. Many customers may not yet know their Clarivate contract is now with Insira.
Customer churn risk during ownership transition. Enterprise pharma contracts renewing in late 2026 and 2027 face a new counterparty (Insira/Altaris), potentially new pricing, and uncertain product roadmap. PE-backed transitions historically create an evaluation window where customers consider alternatives.
No published customer validation of agentic AI capabilities. Three months post-launch, neither customer testimonials, G2 reviews, nor case studies have confirmed production adoption of the August 2026 agentic AI features. This stands in contrast to competitors like AlphaSense, which publishes usage metrics (2B AI actions annualized) and customer quotes regularly.
Data platform, not CI deliverable producer. Cortellis CCI provides intelligence data and tools — not finished CI deliverables, scenario analyses, war-gaming frameworks, or strategic recommendations. For CI practitioners who need insight, not just information, Cortellis is an input, not an output. The agentic AI claims to close this gap but remains unvalidated.
Price opacity and cost. Enterprise-only pricing with no published rates is consistently noted across review platforms. At $50K–$270K+ per year, Cortellis is priced for large pharma — leaving mid-market biotech and lean CI teams underserved.
Transition services dependency. Post-divestiture, Insira operates under a transition services agreement with Clarivate, which includes a $25M deferred payment tied to completion. Shared AI infrastructure, IT systems, and operational processes must be migrated to Insira's independent stack — a multi-quarter effort that diverts engineering resources from product development.
Product complexity. Industry reviews note Cortellis can be "complex and costly for some users," with exporting, API access, and data normalization requiring additional configuration and governance.
Based on the analysis of Insira's goals, strategy, assumptions, and capabilities, here's how they're likely to behave over the next 12 months.
Cross-platform AI integration with Simulations Plus/CCG. Expect announcements in H1 2027 connecting CCI agentic workflows with SLP biosimulation data — e.g., CCI pipeline intelligence enriched with GastroPlus PBPK modeling or ADMET toxicity predictions. This would create a differentiated offering no competitor can match.
MCP ecosystem expansion. CRI and CMC Intelligence already have Claude and Copilot connectors. Expect CCI (competitive intelligence) and CDDI (drug discovery) MCP endpoints in 2027, making Insira's data accessible from any enterprise AI agent.
Price increases at renewal. Under PE ownership, expect 5–15% price increases for existing contracts, potentially with AI capabilities separated into premium tiers or usage-based pricing for agentic features.
DRG consulting expansion. The KYBORA partnership (M&A advisory) signals intent to expand DRG from a data business into a services business. Additional partnerships or acquisitions in market access consulting, HEOR, or CI advisory are likely.
Aggressive brand establishment. ISPOR Europe 2026 is the first of what will likely be a heavy conference presence in 2027 to establish the Insira brand with pharma decision-makers. Expect increased thought leadership output, new annual reports, and sponsored content.
Rebrand confusion (now through mid-2027). The transition from Clarivate to Insira creates 6–12 months of brand uncertainty during which customers may evaluate alternatives. Procurement teams must update vendor records, legal must review contract novation, and CI teams must explain the ownership change to internal stakeholders.
Transition services dependency (now through mid-2027). Insira's reliance on Clarivate's shared infrastructure for AI, IT, and operations means the company cannot fully control its product development velocity until migration is complete.
Unvalidated AI claims (now). The gap between Insira's AI messaging ("anticipatory intelligence," "agentic workflows") and the lack of published customer validation creates a credibility window that competitors can exploit.
PE pricing pressure (2027 renewal cycle). The first full renewal cycle under Altaris ownership will test customer loyalty against expected price increases. Budget-constrained CI teams may explore alternatives.
For CI practitioners and buyers evaluating Insira, the following areas warrant ongoing monitoring:
US Monthly Search Volume ("insira"): 8,100 (Internal keyword research)
Keyword Cluster Volume: 39,800 (Internal keyword research)
Keyword Difficulty: 39% (Internal keyword research)
CPC: $3.59 (Internal keyword research)
Keyword Variations: 4,172 (Internal keyword research)
As of November 2026, most search volume still flows through legacy queries — "clarivate," "cortellis," "clarivate life sciences" — rather than "insira." The brand is too new for significant navigational search volume. Over the next 6–12 months, SEO equity will gradually shift from Clarivate-associated terms to Insira-branded queries. CI.com has an opportunity to rank for "insira" and "insira competitors" before the competitive SERP matures.
clarivate competitors: est. 100+
cortellis competitors: est. 50+
what is clarivate: 140 (62%)
insira competitors: emerging
insira clarivate: emerging
This section links to the most recent Vendor Intelligence Feed posts for Insira. Updated as new signals are published.
This profile is maintained as a living document. When new intelligence signals change any of the four Porter components — goals, strategy, assumptions, or capabilities — the relevant sections are updated. For the latest intelligence briefs on Insira, visit the Vendor Intelligence Feed.
© 2026 CompetitiveIntelligence.com. Independent analysis by Alex Von. All factual claims sourced with hyperlinks.